Active	Status	Sponsor type	Region	Phase	Filter
3 Active 1 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Wu, Peng
NCT06654011: IN10018 with Nab-Paclitaxel and Cadonilimab for Metastatic or Recurrent Gastric-Type Cervical Adenocarcinoma: Phase 2 Trial	Not yet recruiting	2	25	RoW	IN10018, BI 853520, Nab-paclitaxel, Albumin-bound paclitaxel, Cadonilimab, AK104	Wuhan Union Hospital, China	Cervical Adenocarcinoma	05/26	11/26
NCT04479553: Post-marketing Safety Surveillance of Qizhi Tongluo Capsules:a Registry Study.	Recruiting	N/A	30000	RoW	Qizhi Tongluo Capsules	Zhong Wang, Shanxi Zhendong Pharmacy Co., Ltd	Safety Surveillance, Adverse Drug Events, Adverse Drug Reactions, Severe Adverse Events, Severe Adverse Reactions	09/23	12/23
NCT06155539: A Study of Blood Metabolic Markers in Patients With Type 2 Diabetes Mellitus of Different Stages	Not yet recruiting	N/A	105	RoW	No intervention	Peng Wu	Diabetes Mellitus, Type 2	05/25	12/25